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MEASUREMENT PROPERTIES OF THE SPANISH VERSION OF THE PEDIATRIC
PROMIS FATIGUE ITEM BANK
Lai JS, Correia H, Cella D
Northwestern University, Chicago, IL, USA
OBJECTIVES: Fatigue is common among children with chronic conditions. In order
to compare results across languages, a requirement for many clinical trials, one
must ensure measurement is not biased by language. This paper reports the psy-
chometric properties of the Spanish version of the pediatric PROMIS (Patient Re-
ported Outcomes Measurement Information System) fatigue item bank (Spanish-
PedsFIB). Developed via a collaborative effort funded by the National Institutes of
Health of the United States, PROMIS allows for comparisons across domains and
conditions for both adults and children.METHODS: Data from 605 Spanish-speak-
ing participants, recruited from a US general population panel, were analyzed.
Average age was 12.3 years and 45.5% were female. Participants completed the
23-item Spanish-PedsFIB, translated from English via a rigorous methodology (2
forward translations, 1 reconciliation, 1 back-translation, review by bilingual ex-
perts, and cognitive debriefing). Psychometric analyses included confirmatory fac-
tor analysis (CFA) to evaluate unidimensionality (criteria: comparative fit index CFI
 0.95; RMSEA  0.08, MI 10), residual correlations to evaluate local dependency
(criterion: r0.15), S-G2 and S-2 to evaluate item fit (criterion: p 0.01). Graded
Response Model as implemented in MULTILOG was used to estimate item param-
eters, and LORDIF (R freeware) was used to evaluate differential item functioning
between the Spanish and English versions (criteria: p.01). RESULTS: CFA results
supported unidimensionality of these 23 items: CFI0.995, RMSEA0.056, residual
correlation absolute values ranged from 0 to 0.05, and R2 ranged from 0.69 and 0.87.
One item had poor fit with p0.0041 and 0.0093 for S-G2 and S-2, respectively. Six
items (measuring more severe fatigue) exhibited significant DIF. Correlation be-
tween scores with and without DIF candidate items was 0.97. CONCLUSIONS: Ex-
cellent psychometric properties of the Spanish version of Spanish-PedsFIB were
evidenced. Comparative studies can be conducted using the English and Spanish
versions. Currently, more translations are in progress.
RESEARCH ON METHODS - Statistical Methods
PRM39
SURVIVAL CURVE CONVERGENCES AND CROSSING: A THREAT TO VALIDITY OF
META-ANALYSIS?
Kristiansen IS
University of Oslo, Oslo, Norway
OBJECTIVES:When data from survival analysis are summarized in meta analysis,
they are usually based on the number of events at the end of the study. This will
bias the estimates of differences in survival unless the relative hazards are rela-
tively constant (the proportional hazards assumption). The aimof this studywas to
explore this assumption by estimating the frequency of convergences and cross-
ings of survival curves. METHODS: We reviewed all publications in Annals of In-
ternal Medicine, British Medical Journal, JAMA, New England Journal of Medicine
(NEJM) and The Lancet for 2007 and identified studies that included survival
graphs. We extracted the following data from included studies: type of disease,
type of exposure, sample size and number of events, maximum follow-up time,
number and timing of survival curve convergences and crossings, andwhether Cox
regression and log-rank tests had been performed. RESULTS: Among 175 included
studies, 35% had survival curve convergences and 47% crossings. 38% of the cross-
ings occurred later than halfway through the study (40% for convergences). The
proportion of crossings by type of disease was 46% for cardiovascular disease, 38%
for cancer and 53% for other diseases. Among studieswith survival curve crossings,
Cox regression was performed in 66% and logrank-test in 70% of the studies. Only
31% of all the studies reported testing for proportional hazards when Cox regres-
sion had been employed. CONCLUSIONS: Survival curve convergences and cross-
ings are common in medical research. Effectiveness estimates based on end of
study resultswill likely be biased unless convergences and crossings are accounted
for, and this bias will carry over tometa analyses of individual studies. Researchers
frequently employ Cox modeling when the proportional hazard assumption is not
met or use log rank tests when other test would be more appropriate.
PRM40
APPLYING STRATIFICATION ON TIME TO OVERCOME TIME-VARYING
COVARIATES EFFECTS IN COX PROPORTIONAL HAZARDS MODELS
Abdul Aziz SH1, Azmi S1, Goh A1, Naing NN2
1Azmi Burhani Consulting, Petaling Jaya, Selangor, Malaysia, 2Universiti Sains Malaysia,
Kubang Kerian, Kelantan, Malaysia
OBJECTIVES: Cox proportional hazards models are widely used in the analysis of
survival data to explain the effects of prognostic factors on survival time. The
model assumes proportionality of prognostic factors over time. Prognostic factor
values, however, are often not constant over time, causing time-varying covariate
(TVC) effects. In order to overcome this problem, a helpfulmethod is to incorporate
stratification on time. This study estimates the survival of chronic renal failure
(CRF) patients using the abovemethod.METHODS:This analysis was conducted on
data from 145 patients in a Malaysian government hospital. The assumption of
proportionality was analyzed by using log cumulative hazards curves plotted
against log time (log-minus-log) and Schoenfeld residuals and scaled Schoenfeld
partial residuals. TVC was analyzed by the interactions of prognostic factors with
log time. Violation of the proportionality assumption was overcome by stratifica-
tion on time of the prognostic factors. RESULTS: Median survival time of CRF pa-
tients in the study was estimated at 4.5 years. The significant prognostic factors
were ex-smokers (p0.043), current smokers (p0.035) and post-renal failure hy-
pertension (p0.054). The proportionality assumption was violated in the ex-
smokers’ factor as shown by log-minus-log and Schoenfeld residuals and scaled
Schoenfeld partial residuals. Stratification on time at 0.8 years was applied to cor-
rect the problem. CONCLUSIONS: Survival analysis in this study using the Cox
proportional hazards model was affected by the TVC effect on the ex-smokers as a
prognostic factor. Stratification on time was able to overcome this problem.
RESEARCH ON METHODS - Conceptual Papers
PRM42
MULTIPLE CRITERIA DECISION ANALYSIS FOR HEALTH TECHNOLOGY
ASSESSMENT
Thokala P
University of Sheffield, Sheffield, UK
OBJECTIVES: This paper will discuss the different methods of multi criteria deci-
sion analysis (MCDA) that could be used in health technology assessment (HTA)
and their relative merits.Description: The current practice of health technology
appraisals is based on the incremental cost-effectiveness ratio (ICER) i.e. the incre-
mental cost per quality adjusted life year (QALY) gained by recipients of treatment.
Even though other factors (e.g. severity, life saving, etc) are considered along with
ICERs, there is concern that its approach may fail to capture other important
sources of value. METHODS: MCDA is aimed at supporting decision makers faced
with evaluating alternatives taking into account multiple, and often conflictive,
criteria in an explicit manner. An overview of MCDA is provided and is compared
against the current health technology appraisal processes. A number of important
questions are addressed to identify themost appropriateMCDAmethod thatmight
be used to support decision making. For example, what criteria should be incorpo-
rated? Whose weights should be used and how to elicit them? How to incorporate
uncertainty into the MCDA process? How do we consider the value of displaced
technologies? What should the ‘basic’ cost-effectiveness threshold be? How do we
estimate it? This paper will discuss these questions, outline and assess method-
ological issues that would be raised by the use of MCDA in health technology
assessment (HTA). RESULTS:Most of the proposed MCDA approaches in literature
use the same technique (weighted sum approach), however, more flexible ap-
proaches are available that are relevant to health technology appraisal and value
based pricing (VBP). CONCLUSIONS: There are general practical issues that might
arise from using this MCDA approach in the HTA process and further research
needs to be performed to address the issues identified in order to ensure the suc-
cess of this MCDA technique in the appraisal process.
PRM43
ROLES AND SELECTION OF COMPARATIVE TREATMENT(S) IN THE
ASSESSMENT OF NEW DRUG REIMBURSEMENT AND PRICING APPLICATION TO
TAIWAN NATIONAL HEALTH INSURANCE (NHI)
Shau WY, Wang JC
Center for Drug Evaluation, Taipei, Taiwan
The Principles on Drug Reimbursement Price Approval(PDRPA) is the basis for pricing
new pharmaceuticals for NHI reimbursement in Taiwan. PDRPA describes the
scope of comparative treatments and defines the 3Categories of new drug as: 1
(breakthrough); 2A (moderate improvement); and 2B (similar) based on the com-
parative effectiveness of new drug to the current therapies, which links to the
decision of pricing method used. The selection of comparator is crucial in technol-
ogy assessment and has profound influence on the pricing decision. Hereby we
explicitly describe the selection rules and roles of comparator(s). To sort out the
rationale of comparator selection, the following 8 features of a comparator are
considered: 1) indication(s) approved by department of health Taiwan; 2) associ-
ated reimbursement guidance; 3) ATC (Anatomical Therapeutic Chemical) classi-
fication; 4) clinical guidance of using the comparator on treating target disease by
new drug; 5) comparative evidence such as head-to-head trial or indirect compar-
ison; 6) NHI reimburse price; 7) prices of comparator in the 10 reference countries;
and 8) recent utilization in NHI. Clinical relevant and appropriateness are the pri-
ority of comparator(s) selection. To be qualified as class 1 or 2A new drug, the
currently best therapy should be used as comparator. Then one of the 6 pricing
methodswill be chosen to decide the reimbursement price of the new drug, with or
without reimbursement guidance on using the new drug; and/or the decision to
initiate price-volume agreement or (financial) risk sharing negotiation with the
pharmaceutical company. Five possible roles of the comparator(s) would play in
the assessment: 1) to justify the comparative effectiveness to the new drug; 2) to
calculate the price of new drug; 3) to evaluate the net budget impact; 4) as reference
setting for reimbursement guidance; and 5) be used in pharmacoeconomic study.
PRM44
CLINICAL AND COMPARATIVE ECONOMIC VALUE - A NOVEL
PHARMACOECONOMIC ANALYSIS EMBEDDED IN THE DRUG DEVELOPMENT
PROCESS
Fang X1, Seo M1, Standing M2, Xu Z1, Jacobson S3, Woolmore A4
1Monitor Group Shanghai, Shanghai, China, 2Monitor Group London, London, UK, 3Monitor
Group New York, New York, NY, USA, 4Monitor Group Paris, Paris, France
OBJECTIVES: Pharmaceutical companies are under pressure to assess the eco-
nomic value of their pipeline assets. Pharmacoeconomic (PE) analysis can be em-
ployed to improve the decision-making process by providing robust estimations of
comparative economic value before the commercial launch. Clinical and Compar-
ative Economic Value (CCEV)methodology, has been developed to provide insights
into the sources of economic values of innovative products (drugs, devices, ser-
vices) to inform critical decisions across the product life cycle.METHODS: Amulti-
state disease model is developed to simulate the major clinical events in the dis-
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ease progression. Real-world data on actual health care resource consumption and
patient clinical characteristics are used. Time horizon of themodels should be long
enough to capture meaningful differences in outcomes. The differential clinical
attributes of the products are identified and direct links are established with the
corresponding economic values. The resulting impact on disease progression and
consequences for consumption of health care resources are simulated. The pri-
mary output is the cost-avoidance against the chosen comparator, with corre-
sponding breakdown by each clinical attribute. RESULTS: CCEV directly translates
the differences in clinical outcomes to the differences in economic values. This
methodology has been effectively applied in the decision process at different
stages of drug development, such as, to prioritize pipeline assets by comparing the
potential economic value of assets under development and quantifying the value
of each differentiated output. These insights are used to guide and design the
following data generation strategies. CONCLUSIONS: CCEV methodology directly
translates clinical outcomes to economic values and is a practical PE tool for deci-
sion makers. It can be employed across the entire product life-cycle, starting from
the early stages of drug development.
PRM45
ARE MINIMAL CLINICALLY IMPORTANT DIFFERENCE MEASURES (MCIDS)
RELEVANT FOR SURVIVAL OUTCOMES? INTRODUCING THE MCID-CAC
Standfield L, Weston A
OptumInsight, Sydney, NSW, Australia
Minimal Clinically Important Difference margins (MCIDs) are being applied by re-
imbursement agencies to assess the non-inferiority of new medications against
comparator medications in the Asia Pacific Region. If a new medication is deemed
non-inferior to an all ready reimbursed medication either via direct or indirect
comparison methods the newer product is generally reimbursed at the same price
as the comparator medication (ie. through cost-minimisation). The concept of an
MCID margin for survival outcomes, however, is problematic and controversial. A
superficial consideration of MCIDs for survival outcomes may lead to the conclu-
sion that the MCID for survival is inappropriate and no difference in survival is
acceptable. As such, the MCID for survival should be zero. In this case such an
analysis would become a superiority analysis. If this approach to the assessment of
such products were to prevail, new products with a high likelihood of affording
patients a survival benefit compared to their comparator products may be rejected
even on a cost-minimisation basis. Instead, where the point estimate of treatment
effect favours the new treatment serious consideration should be given to reim-
bursing the new product at the same or higher price. Using indirect comparison
methods and real world hazard ratio data this research introduces the concept of
MCID-cumulative acceptability curves (MCID-CAC) as an aid to making pragmatic
reimbursement decisions for new products that may extend patients lives.
DISEASE-SPECIFIC STUDIES
CANCER-Clinical Outcomes Studies
PCN1
BISPHOSPHONATES AND RISK OF OSTEONECROSIS OF JAW IN CANCER
PATIENTS: A META-ANALYSIS
Leung HW1, Chan A,L2, Ko J2
1Wan-Fang Hospital, Taipei, Taiwan, 2Min-Sheng General Hospital, Taoyuan, Taiwan
OBJECTIVES: This meta-analysis aims to assess the potential risk of osteonecrosis
of jaw and bisphosphonate use in cancer patients . METHODS: The published
literature was systematically searched and reviewed usingMEDLINE (1950 through
July 2011), EMBASE (1980 through July 2011), and the Cochrane Central Register of
Controlled Trials (The Cochrane Library 2011 issue 1). Studies that included specific
risk estimates were pooled using a random-effects model. The bias and quality of
these studies were assessed with RevMan statistical software (version 5.0) and the
GRADEmethod of the Cochrane Collaboration. RESULTS: A total of 32 publications
met inclusion criteria, but only 9 studies that included 51580 subjects for analysis.
No randomized controlled clinical trials, meta-analysis or quality of life articles
were found that contained data for risks or prevalence of osteonecrosis. The results
of a meta-analysis that pooled data from 10 cohort studies indicated that the over-
all multivariable odds ratio and hazard ratio were 1.11 (95% CI: 0.15, 8.47 ) and 0.35,
23835 , respectively (95% CI 0.51 to 1.00; p  1.00), respectively. The risk of osteo-
necrosis associated with biophosphonate was statistically significant. The results
of the quality assessment of these studies indicated low scores using the GRADE
method. CONCLUSIONS: The uses of bisphosphonates is likely to be associated
with the increased risk of osteonecrosis of jaw in cancer patients.
PCN2
THE RELATIONSHIP OF FOLLOWING LIPID-LOWERING DRUGS USED WITH
ADJUVANT HORMONAL THERAPY IN BREAST CANCER WOMEN
Chang YC1, Lin SJ2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kohsiung Medical University, Kaohsiung,
Kaohsiung, Taiwan
OBJECTIVES: Extended adjuvant hormonal therapywith aromatase inhibitors (AIs)
or tamoxifen can both effectively reduce the recurrence of breast cancer, but the
potential of change lipid profile with AIs compared to tamoxifen was observed in
some clinical studies. The aim of this study was to evaluate whether the hormone
adjuvant therapywill increase the prescribing rate of lipid-lowering drugs (LLDs) in
breast cancer women. METHODS: A retrospective cohort study was conducted
using the National Health Insurance Research Database between January 1997 and
December 2008. The inclusion criteria were adult women who were newly diag-
nosed with breast cancer and without past history of hyperlipidemia or other can-
cer diseases between 1998 and 2008. The study endpoint was defined as emerging
of the first prescription of LLDs within the exposure period. Adjusted hazard ratio
(HR) for the first LLDs prescription was analyzed using multivariable Cox propor-
tional hazards regression model. RESULTS: There were 378, 1148 and 756 breast
cancer patients treated with AIs, tamoxifen and didn’t receive hormonal therapy,
respectively. Compared to the non-hormonal therapy cohort, the rate of prescrib-
ing LLDs was lower in patients who treated with tamoxifen after adjusted age and
comorbidity (HR0.68, [95% CI0.46-0.99]), and non-significantly increased in pa-
tients who treated with AIs (HR1.12 [95% CI0.65-1.91]). In addition, the prescrib-
ing LLDs rate between AIs treatment and treatment with tamoxifen was non-
significantly increased (HR1.41 [95% CI0.83-2.83]) in the head to head
comparison. CONCLUSIONS: Results from this study indicated that AIs does not
significantly increase the risk of prescribing LLDs compare to the patients without
hormonal therapy. In contract, the tamoxifen therapy was significantly reduced
the prescription rate of LLDs, thus tamoxifen might had potential benefit on lipid
metabolism.
PCN3
IMPROVEMENT OF THE 3RD GENERATION COLORECTAL CANCER GENE CHIP
Syu FK
Han-Ming Hospital, Changhua City, Taiwan
OBJECTIVES: Colorectal Cancer (CRC) has now become the second leading cause of
death in Taiwan, and is one of the cancers with highest incidence in women. Our
goal is to integrate comprehensive information to determine the relation between
omics and clinical pathology by a systematic biomedical approach and further
improve our third generation gene chips for higher sensitivity and specificity to-
ward colorectal cancer.METHODS: : One hundred and five patients colorectal can-
cer patients who had undergone curative surgical resection of colorectal cancer
were studied. The copy number for each SNP probe set taken from a tumor sample
was calculated by comparing the probe intensity to the reference probe intensity
from non-neoplastic tissue, and creating a list of the genome-wide copy number
data. RESULTS: Among 105 patients with a median follow-up period of 5.6 years
(range, 4.1-10.8 years), 23 developed early disease recurrence, whereas 82 did not.
Most of themweremale and less than 60 years (p0.044). Stage III, deeper invasive
tumor (T3 T4) and positive lymph node metastasis could be found seriously by
70.5%, 92.4%, and 68.6%, respectively. CEA, EV12B, ATP2A2, S100B, KLK7, TM4SF3,
and OLFM4 had copy number gains and high expression levels (P 0.05) in no
recurrence vs. recurrence. CONCLUSIONS: Patients less than 60 years were signif-
icantly risky to get early relapse in colorectal cancer. In comparison to traditional
colorectal cancer gene chip, we would weight higher on EV12B (RR 4.622, 95% CI
1.741-12.270, p0.001), ATP2A2 (RR 4.688, 95% CI 1.443-15.232, p0.006), and S100B
(RR 11.521, 95% CI 2.688-49.377, p0.0001).
PCN4
ROLE OF 5-ALPHA-REDUCTASE INHIBITORS, STATINS, ASPIRIN, NSAIDS ON
THE DEVELOPMENT OF PROSTATE CANCER IN BENIGN PROSTATIC
HYPERPLASIA PATIENTS-A POPULATION BASED STUDY
Chen SH, Wen YH, Huang YB, Chen JJ, Yang YH
Kaohsiung Medical University, Kaohsiung, Taiwan
OBJECTIVES: The 5-alpha-reductase inhibitors (5-ARIs), statins, aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) were previously reported to have pro-
tection effect for prostate cancer. The aim of this study was to simultaneously
investigate these drug effects on prostate cancer risk among benign prostatic hy-
perplasia (BPH) patients. METHODS: Newly diagnosed BPH patients (ICD-9-CM
code: 185 and A-code: A124) with at least one prescription of BPH medications
(5-ARIs, alpha-blockers) were identified from Taiwan Longitudinal Health Insur-
ance Database 2000 in 1998-2008. Drug usages of 5-ARIs, statins, aspirin, traditional
NSAIDs (tNSAIDs), and cyclooxygenase-2 (COX-2) selective inhibitors were com-
puted in terms of define daily dose (DDD), and were further categorized into high
and lose dose groups bymedians. The Cox regression was used to estimate hazard
ratios (HRs) for the occurrence of prostate cancer. Additional covariates in the
model included age, time-dependent covariates of drug usages and Charlson co-
morbidity score. RESULTS: There were 758 prostate cancers indicated from the
registry dataset for catastrophic illness patients from 41,955 BPH patients. The
analysis of all studied drugs showed significant protection HRs from univariate
analyses. After adjusting for covariates, the multivariable analysis showed signif-
icant protection effects on high dose of 5-ARIs (HR0.47, 95%CI 0.26-0.99), on high
dose of statins (HR0.56, 95%CI 0.38-0.83), on both low and high dose of tNSAIDs
(HR0.42, 95%CI 0.36-0.50; HR0.25, 95%CI 0.20-0.31), and on both low and high
dose of aspirin (HR0.73, 95%CI 0.60-0.88; HR0.34, 95%CI 0.26-0.45). The COX-2
selective inhibitors became not significant. CONCLUSIONS: The 5-ARIs, statins,
tNSAIDs, aspirin and COX-2 selective inhibitors have been separately investigated
their protection effects on the development of prostate cancer. Our results indi-
cated that the protection effects of 5-ARIs, statins, tNSAIDs and aspirin were inde-
pendently significant. In addition, the protection effect fromCOX-2 selective inhib-
itors was appeared to be confounded by other medication.
PCN5
IMPACT OF ERYTHROPOIESIS STIMULATING AGENTS ON SURVIVAL AMONG
PATINETS WITH COLORECTAL CANCER RECEIVING CHEMOTHERAPY
Sato M1, Freedman A2, Trovato J1, Zhan M3, Cunningham F4, Weiss Smith S1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2National Cancer Institute,
Bethesda, MD, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA, 4Veterans
Health Administration Pharmacy Benefits Management Services, Hine, IL, USA
OBJECTIVES: To evaluate the effect of Erythropoiesis stimulating agents (ESAs) use
on survival among colorectal cancer patients undergoing chemotherapy.
METHODS: This study was a nonconcurrent prospective cohort study using the
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